Royal Bank of Canada
CRDL

Royal Bank of Canada’s Cardiol Therapeutics CRDL Stock Holding History

Royal Bank of Canada’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7K Sell
6,729
-14,919
-69% -$18.9K ﹤0.01% 6820
2026
Q1 		$29K Buy
21,648
+8,306
+62% +$8.52K ﹤0.01% 5738
2025
Q4 		$13K Buy
13,342
+892
+7% +$934 ﹤0.01% 6275
2025
Q3 		$13K Sell
12,450
-7,854
-39% -$9.53K ﹤0.01% 6378
2025
Q2 		$28K Buy
20,304
+7,490
+58% +$8.72K ﹤0.01% 6148
2025
Q1 		$12K Sell
12,814
-11,987
-48% -$14.7K ﹤0.01% 6086
2024
Q4 		$32K Buy
24,801
+671
+3% +$1.13K ﹤0.01% 5896
2024
Q3 		$48K Sell
24,130
-2,975
-11% -$6.17K ﹤0.01% 5715
2024
Q2 		$55K Buy
27,105
+10,676
+65% +$22.7K ﹤0.01% 5599
2024
Q1 		$31K Sell
16,429
-17,678
-52% -$23.8K ﹤0.01% 5726
2023
Q4 		$28K Sell
34,107
-10,342
-23% -$8.79K ﹤0.01% 6203
2023
Q3 		$40K Buy
44,449
+5,728
+15% +$5.47K ﹤0.01% 5890
2023
Q2 		$34K Sell
38,721
-13,905
-26% -$9.18K ﹤0.01% 5952
2023
Q1 		$25K Buy
52,626
+26,475
+101% +$15.7K ﹤0.01% 5938
2022
Q4 		$13K Sell
26,151
-3,288
-11% -$2K ﹤0.01% 6442
2022
Q3 		$30K Buy
29,439
+6,125
+26% +$7.47K ﹤0.01% 5974
2022
Q2 		$31K Sell
23,314
-11,900
-34% -$16.9K ﹤0.01% 5920
2022
Q1 		$54K Buy
35,214
+14,020
+66% +$23.1K ﹤0.01% 6032
2021
Q4 		$39K Buy
21,194
+6,999
+49% +$19.3K ﹤0.01% 6509
2021
Q3 		$59K Buy
+14,195
New +$51.4K ﹤0.01% 6064

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada's CRDL Position: Q2 2026 in Review

Royal Bank of Canada reduced its Cardiol Therapeutics (CRDL) stake by 69% in Q2 2026, selling an estimated $18.9K and leaving 6,729 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #6820.

Royal Bank of Canada first reported a position in CRDL in Q3 2021 and has held it in 20 quarters since. The position peaked at $59K in Q3 2021. 51 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Royal Bank of Canada held 6,729 shares of Cardiol Therapeutics worth $7K as of Q2 2026.
  • Royal Bank of Canada sold 14,919 Cardiol Therapeutics shares in Q2 2026, an estimated $18.9K.
  • Cardiol Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6820 holding.
  • Royal Bank of Canada first reported a position in Cardiol Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Royal Bank of Canada's Cardiol Therapeutics position peaked at $59K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.